Small-molecule SOS1 inhibitor, BI-3406, interacts with the catalytic domain of SOS, resulting in interference with the interaction with KRAS and thereby restricting tumor cell proliferation in KRAS-mutant cancer, including G12 and G13 [59]. Here, KRAS is linked to neoplasm.